Ata Ppgl Surveillance Intensity Determination

---
name: ata-ppgl-surveillance-intensity-determination
description: This skill determines postoperative surveillance intensity for pheochromocytoma and paraganglioma based on hereditary status, catecholamine phenotype, tumor size, and location. Use when a clinician asks 'How long and how often should I follow up this pheochromocytoma patient after surgery?' with triggers such as completed PPGL resection, hereditary PPGL, sporadic PPGL with noradrenaline dominance, tumor diameter ≥5 cm, or extra-adrenal location outside head/neck.
---

# Determine postoperative surveillance intensity for pheochromocytoma and paraganglioma

## STEP 1 — Gather Information
Collect postoperative pathology report (hereditary vs sporadic), catecholamine phenotype (noradrenaline dominance from fractionated metanephrines), tumor diameter, anatomic location (adrenal vs extra-adrenal, head/neck vs other), germline genetic testing results if available, patient age.

## STEP 2 — Rule In / Rule Out
Determine if the PPGL is hereditary (germline pathogenic variant in SDHx, VHL, RET, NF1, etc.). If yes, proceed to lifelong follow-up; if no, continue to risk stratification for sporadic PPGL.

## STEP 3 — Classify or Stratify
For sporadic PPGL, assess for high-risk features: noradrenaline dominance, primary tumor diameter ≥5 cm, or extra-adrenal location outside the head/neck. Presence of any high-risk feature indicates need for extended (≥10‑year) surveillance; absence of all three still warrants a minimum 10‑year follow‑up per guideline.

## STEP 4 — Decide
Implement surveillance schedule: obtain plasma‑free fractionated metanephrines (or urinary fractionated metanephrines with creatinine correction) every 6‑12 months; perform anatomic imaging (CT/MRI, 123I‑MIB​G scintigraphy, or 18F‑FDG PET as clinically indicated) annually if biochemical results are abnormal or if the tumor was non‑catecholamine‑producing; for hereditary or high‑risk sporadic cases, continue imaging every 1‑2 years indefinitely; for low‑risk sporadic cases, limit imaging to biochemical‑triggered studies and discontinue routine imaging after 10 years if all studies remain normal.

## Clinical Guardrails / Mimics / Pitfalls
Do not discontinue surveillance before 10 years even with normal biomarkers; avoid relying on imaging alone in catecholamine‑producing tumors without concurrent biochemical testing; remember that plasma‑free fractionated metanephrines may be measured only once per year under Japanese health insurance, so space tests accordingly; do not overlook extra‑adrenal PGLs outside the head/neck as high‑risk; genetic testing negative does not exclude hereditary syndrome if clinical suspicion remains.

## Concrete Clinical Example
A 52‑year‑old woman undergoes laparoscopic resection of a 5.5 cm left adrenal pheochromocytoma with noradrenaline dominance; germline testing is negative. Post‑operatively she is classified as sporadic PPGL with a high‑risk feature (tumor ≥5 cm and noradrenaline dominance). Surveillance is planned with plasma‑free fractionated metanephrines every 6 months and abdominal MRI annually; if biomarkers stay normal, imaging continues for at least 10 years and then reconsidered.

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165